title: Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.
abstract: Tavaborole topical solution, 5% (tavaborole) is a novel, boron-based, antifungal pharmaceutical agent indicated for treatment of toenail onychomycosis due to the dermatophytes Trichophyton rubrum or Trichophyton mentagrophytes. In preclinical studies, tavaborole effectively penetrated through full-thickness, non-diseased cadaver fingernails, including those with up to four layers of nail polish. Limited systemic absorption was observed following topical application of tavaborole. In phase III clinical trials involving patients with distal subungual onychomycosis affecting 20-60% of a target great toenail, significantly more patients treated with tavaborole versus vehicle achieved completely clear nail with negative mycology following daily application for 48 weeks. Treatment-emergent adverse events reported by at least 1% of patients treated with tavaborole and at a greater frequency versus vehicle included ingrown toenail, exfoliation, erythema and dermatitis. Treatment discontinuations were uncommon. Results from preclinical studies and phase III clinical trials establish tavaborole as a safe and efficacious treatment for toenail onychomycosis.
authors.affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, USA. LZane@anacor.com.
authors.forename: L T
authors.initials: LT
authors.lastname: Zane
authors.affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, USA.
authors.forename: J
authors.initials: J
authors.lastname: Plattner
authors.affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chanda
authors.affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, USA.
authors.forename: D
authors.initials: D
authors.lastname: Coronado
authors.affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, USA.
authors.forename: T
authors.initials: T
authors.lastname: Merchant
authors.affiliation: Anacor Pharmaceuticals, Inc., Palo Alto, California, USA.
authors.forename: M R K
authors.initials: MR
authors.lastname: Alley
authors.affiliation: University of Toronto, Toronto, Ontario, Canada, & Mediprobe Research Inc., London, Ontario, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
mesh_terms: D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage; D001896:Boron Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D004347:Drug Interactions; D005533:Foot Dermatoses / Q000188:drug therapy*; D006801:Humans; D014009:Onychomycosis / Q000188:drug therapy*; D012996:Solutions
chemical_list: D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D012996:Solutions; C512998:tavaborole
keywords: AN2690; Antifungal agents; Onychomycosis; Tavaborole; Trichophyton rubrum